BMX-001
BMX-001 is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
2 of 4 finished
50.0%
2 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Clinical Trials (7)
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7